TABLE 2.
Baseline and treatment characteristics of patients with fatal pneumonitis
| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|---|---|---|---|---|---|---|
| Patient baseline characteristics | ||||||
| Age (years) | 55 | 66 | 70 | 78 | 62 | 68 |
| Sex | M | M | M | M | M | M |
| Histologic type | Small cell | Adenocarcinoma | Squamous | Adenocarcinoma | Squamous | Squamous |
| Disease stage | Ⅳ | Ⅳ | Ⅲ | Ⅳ | Ⅳ | Ⅳ |
| ECOG PS | 0 | 1 | 1 | 1 | 1 | 1 |
| Smoking history (Pack‐years) | 1 | 125 | 20 | 50 | 40 | 75 |
| Pulmonary emphysema | N | Y | N | N | N | Y |
| Interstitial pneumonia/fibrosis | N | Y | N | Y | N | N |
| Treatment line of PD‐(L)1 inhibitor | 1 | 1 | 1 | 1 | 2 | 1 |
| PD‐(L)1 inhibitor type | PD‐1 | PD‐1 | PD‐1 | PD‐1 | PD‐1 | PD‐1 |
| Cycles of PD‐(L)1 inhibitor before TRT | 4 | 11 | 6 | 5 | 6 | 9 |
| Time from the initiation of PD‐(L)1 inhibitor treatment to TRT (months) | 6.0 | 9.5 | 4.3 | 3.2 | 3.7 | 6.8 |
| Dosimetric parameters of TRT | ||||||
| Total dose/fractions | 50 Gy/25f | 60 Gy/30f | 60 Gy/30f | 55.8 Gy/31f | 52 Gy/26f | 36 Gy/20f |
| Total lung V5 (%) | 36.05 | 33.43 | 56.31 | 40.05 | 52.71 | 44.48 |
| Total lung V20 (%) | 23.17 | 15.71 | 25.37 | 12 | 21.57 | 18.02 |
| MLD (Gy) | 11.28 | 8.82 | 13.05 | 8.26 | 11.43 | 9.08 |
| TRT Target area | Parenchyma+DLN | Parenchyma+DLN | Parenchyma | Parenchyma+DLN | Parenchyma+DLN | Parenchyma+DLN |
Abbreviations: M, male; F, female; Y, yes; N, no; ECOG PS, Eastern Cooperative Oncology Group performance status; PD‐(L)1, programmed death 1/programmed death ligand 1; TRT, thoracic radiotherapy; Vx, percentage of total lungs volume receiving no less than xGy; MLD, mean dose of total lungs; DLN, draining lymph node.